Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Leivo Korpela, Sirpa ^a,b   Lehtimäki, Lauri ^a,b   Hämälainen, Mari ^b   Vuolteenaho, Katriina ^b   Kööbi, Lea ^a   Järvenpää, Ritva ^a   Kankaanranta, Hannu ^c   Saarelainen, Seppo ^a   Moilanen, Eeva ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; FLIXOTIDE DISKUS; FLUTICASONE PROPIONATE; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; NESFATIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CYTOKINE; DNA BINDING PROTEIN; FLUTICASONE; NERVE PROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; NUCLEOBINDIN;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; AGED; BLOOD; CASE CONTROL STUDY; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOLOGY; INFLAMMATION; LUNG; MALE; MIDDLE AGED;

ADULT; AGED; ANDROSTADIENES; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; CYTOKINES; DNA-BINDING PROTEINS; FORCED EXPIRATORY VOLUME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUNG; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901802703     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/232167     Document Type: Article

References (44)

1. Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of COPD. 2013, http://www.goldcopd. org/
2. Agustí A., Systemic effects of chronic obstructive pulmonary disease: What we know and what we don't know (but should). Proceedings of the American Thoracic Society 2007 4 7 522 525 2-s2.0-35148893108 10.1513/pats.200701-004FM (Pubitemid 47547846)
3. Barnes P. J., Celli B. R., Systemic manifestations and comorbidities of COPD. European Respiratory Journal 2009 33 5 1165 1185 2-s2.0-66749141807 10.1183/09031936.00128008
4. Wouters E. F., Reynaert N. L., Dentener M. A., Vernooy J. H., Systemic and local inflammation in asthma and chronic obstructive pulmonary disease is there a connection? Proceedings of the American Thoracic Society 2009 6 8 638 647 2-s2.0-74849118542 10.1513/pats.200907-073DP
5. Sinden N. J., Stockley R. A., Systemic inflammation and comorbidity in COPD: a result of"overspill" of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010 65 10 930 936 2-s2.0-77955224519 10.1136/thx.2009.130260
6. Fantuzzi G., Adipose tissue, adipokines, and inflammation. Journal of Allergy and Clinical Immunology 2005 115 5 911 920 2-s2.0-18144408371 10.1016/j.jaci.2005.02.023 (Pubitemid 40616201)
7. Ouchi N., Parker J. L., Lugus J. J., Walsh K., Adipokines in inflammation and metabolic disease. Nature Reviews Immunology 2011 11 2 85 97 2-s2.0-79151484704 10.1038/nri2921
8. Ali Assad N., Sood A., Leptin, adiponectin and pulmonary diseases. Biochimie 2012 94 10 2180 2189 2-s2.0-84858728712 10.1016/j.biochi.2012.03.006
9. Oh-I S., Shimizu H., Satoh T., Okada S., Adachi S., Inoue K., Eguchi H., Yamamoto M., Imaki T., Hashimoto K., Tsuchiya T., Monden T., Horiguchi K., Yamada M., Mori M., Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006 443 7112 709 712 2-s2.0-33749859790 10.1038/nature05162 (Pubitemid 44564715)
10. Ramanjaneya M., Chen J., Brown J. E., Tripathi G., Hallschmid M., Patel S., Kern W., Hillhouse E. W., Lehnert H., Tan B. K., Randeva H. S., Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010 151 7 3169 3180 2-s2.0-77954615466 10.1210/en.2009-1358
11. Tang C. H., Fu X. J., Xu X. L., Wei X. J., Pan H. S., The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides 2012 36 1 39 45 2-s2.0-84860557249 10.1016/j.peptides.2012.04. 014
12. Angelone T., Filice E., Pasqua T., Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cellular & Molecular Life Sciences 2013 70 3 495 509
13. Cetinkaya H., Karagoz B., Bilgi O., Nesfatin-1 in advanced lung cancer patients with weight loss. Regulatory Peptides 2013 181 1 3
14. Cohen R. I., Ginsberg N., Tsang D., Wann L. C., Ye X., Liu S. F., Association of nesfatin-1 and fat mass in cystic fibrosis. Respiration 2013 86 4 312 317
15. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I., Cloning and characterization of the cDNA encoding a novel human pre-B- cell colony-enhancing factor. Molecular & Cellular Biology 1994 14 2 1431 1437 2-s2.0-0027958452
16. Adeghate E., Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Current Medicinal Chemistry 2008 15 18 1851 1862 2-s2.0-52049098545 10.2174/092986708785133004
17. Liu P., Li H., Cepeda J., Zhang L. Q., Cui X., Garcia J. G. N., Ye S. Q., Critical role of PBEF expression in pulmonary cell inflammation and permeability. Cell Biology International 2009 33 1 19 30 2-s2.0-57649155505 10.1016/j.cellbi.2008.10.015
18. Ognjanovic S., Bryant-Greenwood G. D., Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. The American Journal of Obstetrics and Gynecology 2002 187 4 1051 1058 2-s2.0-0036795752 10.1067/mob.2002.126295 (Pubitemid 35178410)
19. Iqbal J., Zaidi M., TNF regulates cellular NAD+ metabolism in primary macrophages. Biochemical and Biophysical Research Communications 2006 342 4 1312 1318 2-s2.0-33644913982 10.1016/j.bbrc.2006.02.109
20. Friebe D., Neef M., Kratzsch J., Erbs S., Dittrich K., Garten A., Petzold-Quinque S., Blüher S., Reinehr T., Stumvoll M., Blüher M., Kiess W., Körner A., Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011 54 5 1200 1211 2-s2.0-79954634068 10.1007/s00125-010-2042-z
21. Curat C. A., Wegner V., Sengenès C., Miranville A., Tonus C., Busse R., Bouloumié A., Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006 49 4 744 747 2-s2.0-33644826101 10.1007/s00125-006-0173-z (Pubitemid 43357549)
22. Moschen A. R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H., Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology 2007 178 3 1748 1758 2-s2.0-33846527541 (Pubitemid 46154646)
23. Luk T., Malam Z., Marshall J. C., Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. Journal of Leukocyte Biology 2008 83 4 804 816 2-s2.0-44449124774 10.1189/jlb.0807581 (Pubitemid 351959859)
24. Ye S. Q., Simon B. A., Maloney J. P., Zambelli-Weiner A., Gao L., Grant A., Easley R. B., McVerry B. J., Tuder R. M., Standiford T., Brower R. G., Barnes K. C., Garcia J. G. N., Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. The American Journal of Respiratory and Critical Care Medicine 2005 171 4 361 370 2-s2.0-13544251479 10.1164/rccm.200404-563OC (Pubitemid 40223404)
25. Gao W., Mao Q., Feng A. W., Sun H. M., Sun W. K., Lu X., Su X., Shi Y., Inhibition of pre-B cell colony-enhancing factor attenuates inflammation and apoptosis induced by pandemic H1N1 2009 in lung endothelium. Respiratory Physiology and Neurobiology 2011 178 2 235 241 2-s2.0-80052387470 10.1016/j.resp.2011.06.016
26. Lehtimäki L., Kankaanranta H., Saarelainen S., Annila I., Aine T., Nieminen R., Moilanen E., Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. European Respiratory Journal 2010 35 1 72 78 2-s2.0-75149122077 10.1183/09031936.00177508
27. Leivo-Korpela S., Lehtimäki L., Vuolteenaho K., Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD. Respiratory Medicine 2014 108 1 122 128
28. Tilg H., Moschen A. R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology 2006 6 10 772 783 2-s2.0-33748992313 10.1038/nri1937 (Pubitemid 44453463)
29. Conde J., Scotece M., Gómez R., López V., Gómez-Reino J. J., Lago F., Gualillo O., Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. BioFactors 2011 37 6 413 420 2-s2.0-84155163931 10.1002/biof.185
30. Sood A., Obesity, adipokines, and lung disease. Journal of Applied Physiology 2010 108 3 744 753 2-s2.0-77949717546 10.1152/japplphysiol.00838.2009
31. Scotece M., Conde J., Vuolteenaho K., Adipokines as drug targets in joint and bone disease. Drug Discovery Today 2014 19 3 241 258
32. Barnes P. J., Shapiro S. D., Pauwels R. A., Chronic obstructive pulmonary disease: molecular and cellular mechanisms. European Respiratory Journal 2003 22 4 672 688 2-s2.0-0141928029 (Pubitemid 37258549)
33. Bazzoni F., Cassatella M. A., Rossi F., Ceska M., Dewald B., Baggiolini M., Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. Journal of Experimental Medicine 1991 173 3 771 774 2-s2.0-0025974730
34. Oki K., Yamane K., Kamei N., Nojima H., Kohno N., Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical Endocrinology 2007 67 5 796 800 2-s2.0-35448980420 10.1111/j.1365-2265.2007. 02966.x (Pubitemid 47628470)
35. Liu X., Ji Y., Chen J., Li S., Luo F., Circulating visfatin in chronic obstructive pulmonary disease. Nutrition 2009 25 4 373 378 2-s2.0-60749115555 10.1016/j.nut.2008.09.008
36. Romacho T., Villalobos L. A., Cercas E., Carraro R., Sanchez-Ferrer C. F., Peiro C., Visfatin as a novel mediator released by inflamed human endothelial cells. PloS ONE 2013 8 10 e78283
37. Hogg J. C., Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. The Lancet 2004 364 9435 709 721 2-s2.0-4344675455 10.1016/S0140-6736(04)16900-6 (Pubitemid 39140629)
38. Eker S., Ayaz L., Tamer L., Ulubas B., Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease. Scandinavian Journal of Clinical and Laboratory Investigation 2010 70 1 40 44 2-s2.0-76749168978 10.3109/00365510903484063
39. Derosa G., Fogari E., D'Angelo A., Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation 2013 36 4 914 920
40. Olszanecka-Glinianowicz M., Kocelak P., Nylec M., Chudek J., Zahorska-Markiewicz B., Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Archives of Medical Science 2012 8 2 214 218
41. Koehler F., Doehner W., Hoernig S., Witt C., Anker S. D., John M., Anorexia in chronic obstructive pulmonary disease-association to cachexia and hormonal derangement. International Journal of Cardiology 2007 119 1 83 89 2-s2.0-34249277021 10.1016/j.ijcard.2006.07.088 (Pubitemid 46818476)
42. Jia S. H., Li Y., Parodo J., Kapus A., Fan L., Holstein O. D., Marshall J. C., Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Journal of Clinical Investigation 2004 113 9 1318 1327 2-s2.0-2342650912 10.1172/JCI200419930 (Pubitemid 39069931)
43. Marcinkowska M., Lewandowski K. C., Lewiński A., Bieńkiewicz M., Basińska-Lewandowska M., Salata I., Randeva H. S., Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans. Endokrynologia Polska 2007 58 3 188 194 2-s2.0-38449117417
44. Klaasen R., Herenius M. M., Wijbrandts C. A., de Jager W., van Tuyl L. H., Nurmohamed M. T., Prakken B. J., Gerlag D. M., Tak P. P., Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Annals of the Rheumatic Diseases 2012 71 9 1510 1516 2-s2.0-84858725710 10.1136/annrheumdis-2011-200646